USA flag logo/image

An Official Website of the United States Government

Development of Ultrafine Particles for Intranasal Delivery of Antipsychotics

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / STTR
Agency Tracking Number:
R41MH098521
Solicitation Year:
2012
Solicitation Topic Code:
NIMH
Solicitation Number:
PA11-133
Small Business Information
LNKCHEMSOLUTIONS
4701 INNOVATION DRIVE LINCOLN, NE -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: Development of Ultrafine Particles for Intranasal Delivery of Antipsychotics
Agency: HHS
Contract: 1R41MH098521-01
Award Amount: $296,413.00
 

Abstract:

DESCRIPTION: The goal of the proposed project is to develop a biocompatible ultrafine particle-based vector system for the intranasal delivery of clozapine for the pharmacological therapy of treatment- resistant schizophrenic disorders and their associatedsuicidal behavior. The rationale behind the use of intranasal clozapine is grounded on the observation of clozapine's extensive first- pass metabolism associated with buccal intake, clozapine's extensive binding to plasma proteins, its short elimination half-life, the absence of significantly active metabolites, and the potentially serious side effects brought about by the high oral doses required for therapeutic benefit. The LNK Chemsolutions LLC/University of Chicago team will use a series of particle design tools, in vivo, ex vivo and in vitro methods to develop the seminal Phase-I level research. Electrohydrodynamic methods will be used to design particles with well-defined sizes and drug payloads, using three different polymers. In vitro drug releaseexaminations will be complemented by muco-adhesive tests, and ex vivo (swine nasal membrane) drug permeation studies. These will guide in vivo (mouse model) studies aimed at elucidating particle and drug transport. PUBLIC HEALTH RELEVANCE: In this SBIR Phase I grant application, LNK Chemsolutions LLC and the University of Chicago researchers are partnering to develop an intranasal drug delivery platform for one anti-psychotic drug. In vitro and in vivo studies will be performed to investigate the potential of the proposed approach.

Principal Investigator:

Sandra E. Noriega
402-416-1811
sandraneb@yahoo.com

Business Contact:

Gustavo Larsen
402-416-1811
LNKChemsolutions@netscape.net
Small Business Information at Submission:

LNKCHEMSOLUTIONS
4701 INNOVATION DRIVE LINCOLN, NE -

EIN/Tax ID: 147083303
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: Yes
HUBZone-Owned: No
Research Institution Information:
UNIVERSITY OF CHICAGO
UNIVERSITY OF CHICAGO
5801 S ELLIS AVE
CHICAGO, IL 60637-
Contact: